学术经历：     受教育经历： 2006-2014年间，申请人先后到英国、瑞士、德国重点实验室学习先进神经成像技术， 并开展临床心理学研究 2006.06-2010.07 德国杜塞尔多夫大学，数学与自然科学部，临床心理学院，心理学，博士。德国科隆大学，医学部，精神病学与精神疗法学院，博士 导师：Prof. E. Gouzoulis-Mayfrank / Prof. R. Pietrowsky 2001.10-2005.06 德国特里尔大学（University of Trier），心理学，硕士。 导师：Prof. G. Krampen / Prof. R. Pukrop 1998.10-2001.03 德国特里尔大学（University of Trier），心理学，本科。 导师：Prof. C. H. Antoni 工作经历： 2015.06-至今 中国电子科技大学，生命科学与技术学院，教授。 2014.01-2014.03 中国电子科技大学，生命科学与技术学院，访问学者（3个月）。 2012.06-2014.12 德国波恩大学，医学心理学系，讲师 2010.08-2014.12 德国波恩大学，精神病学与心理治疗系，博士后研究员 2006.08-2010.07 德国科隆大学，医学部，精神病学与心理治疗系，博士后研究员 2003.12-2010.10 德国科隆大学，护理学院，讲师 2003.08-2003.10 德国科隆大学，精神病学和精神疗法学院，临床实习 2002.02-2002.05 德国科隆大学，差异社会心理学系，研究实习  

个人简介：     Benjamin Becker教授：男，1978年3月出生于德国哈伦，现任电子科技大学生命科学与技术学院教授。2010年7月获得德国杜塞尔多夫大学心理学博士学位，长期从事精神病研究和磁共振技术方面的工作。他致力于发现抑郁障碍等精神疾病的神经网络与病理机制，并以此研发针对精神疾病更有效的治疗方法。申请人近5年来发表SCI论文共计22篇，包括1篇American Journal of Psychiatry（IF=13.559）、1篇Brain (IF=10.226)、2篇PNAS（IF=9.809）、3篇Biological Psychiatry（IF=9.472）、1篇Neuropsychopharmacology（IF=7.833），其中有9篇为第一作者或通讯作者，平均影响因子6.32，最高他引50次。申请人有独立出版专著一本，和关于杏仁核对尼古丁成瘾影响的论著章节一篇，并担任了17本期刊杂志的审稿人，是人类大脑图谱组织（OHBM）和德国心理学会成员，在国际会议中做报告3次，展出海报12次。其中对于癔病性失明、精神分裂症、药物成瘾和杏仁核功能方面的研究为相关领域做出了一定的贡献，具有重要的理论和应用价值。 

科研项目：     2013-2014 德国州科技部（MIWFT）和波恩大学合作基金，项目名称：Galantamine as a potential cognitive enhancer in neuropsychiatric disorders，项目经费：11万欧元，主持者。 2012-2014德国州科技部（MIWFT）和波恩大学合作基金，项目名称：Social-emotional dysfunction in major depression，项目经费：15万欧元，主持者。 2010-2013 德国研究基金（DFG），项目名称：Glutamatergic contributions to nicotine-induced cognitive enhancement，项目经费：27万欧元，参与者（排第一）。 2006-2010 德国研究基金（DFG），项目名称：Long-term consequences of clubdrugs on neurocognitive brain function，项目经费：30万欧元，参与者（排第一）。  

发表文章：     [1] Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J (2010a) Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology (Berl) 209:361-374. [IF 4.06] [2] Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J (2010b) The impact of early-onset cannabis use on functional brain correlates of working memory. Prog Neuropsychopharmacol Biol Psychiatry 34:837-845. [IF 3.55] [3] Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J (2010) Interactions between specific parameters of cannabis use and verbal memory. Prog Neuropsychopharmacol Biol Psychiatry 34:871-876. [IF 3.55] [4] Daumann J, Koester P, Becker B, Wagner D, Imperati D, Gouzoulis-Mayfrank E, Tittgemeyer M (2011) Medial prefrontal gray matter volume reductions in users of amphetamine-type stimulants revealed by combined tract-based spatial statistics and voxel-based morphometry. Neuroimage 54:794-801. [IF 6.25] [5] Becker B, Mihov Y, Scheele D, Kendrick KM, Feinstein JS, Matusch A, Aydin M, Reich H, Urbach H, Oros-Peusquens AM, Shah NJ, Kunz WS, Schlaepfer TE, Zilles K, Maier W, Hurlemann R (2012) Fear processing and social networking in the absence of a functional amygdala. Biol Psychiatry 72:70-77. [IF 8.93] [6] Schnell T, Kleiman A, Gouzoulis-Mayfrank E, Daumann J, Becker B (2012) Increased gray matter density in patients with schizophrenia and cannabis use: a voxel-based morphometric study using DARTEL. Schizophr Res 138:183-187. [IF 4.59] [7] Koester P, Tittgemeyer M, Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J (2012) Cortical thinning in amphetamine-type stimulant users. Neuroscience 221:182-192. [IF 3.12] [8] Striepens N*, Scheele D*, Kendrick KM*, Becker B*, Schafer L, Schwalba K, Reul J, Maier W, Hurlemann R (2012) Oxytocin facilitates protective responses to aversive social stimuli in males. Proc Natl Acad Sci U S A 109:18144-18149. (*co-lead authors) [IF 9.81] [9] Becker B, Wagner D, Koester P, Bender K, Kabbasch C, Gouzoulis-Mayfrank E, Daumann J (2013a) Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study. Psychopharmacology (Berl) 225:923-934. [IF 4.06] [10] Wagner D, Becker B, Koester P, Gouzoulis-Mayfrank E, Daumann J (2013) A prospective study of learning, memory, and executive function in new MDMA users. Addiction 108:136-145. [IF 4.58] [11] Mihov Y, Kendrick KM, Becker B, Zschernack J, Reich H, Maier W, Keysers C, Hurlemann R (2013) Mirroring fear in the absence of a functional amygdala. Biol Psychiatry 73:e9-11. [IF 8.93] [12] Becker B, Scheele D, Moessner R, Maier W, Hurlemann R (2013b) Deciphering the neural signature of conversion blindness. Am J Psychiatry 170:121-122. [IF 14.72] [13] Koester P, Volz KG, Tittgemeyer M, Wagner D, Becker B, Gouzoulis-Mayfrank E, Daumann J (2013) Decision-making in polydrug amphetamine-type stimulant users: an fMRI study. Neuropsychopharmacology 38:1377-1386. [IF 8.68] [14] Becker B, Klein EM, Striepens N, Mihov Y, Schlaepfer TE, Reul J, Goossens L, Schruers K, Kendrick KM, Hurlemann R (2013c) Nicotinic acetylcholine receptors contribute to learning-induced metaplasticity in the hippocampus. J Cogn Neurosci 25:986-997. [IF 4.49] [15] Scheele D, Wille A, Kendrick KM, Stoffel-Wagner B, Becker B, Güntürkün O, Maier W, Hurlemann R (2013) Oxytocin enhances brain reward system responses in men viewing the face of their female partner. Proc Natl Acad Sci U S A 110: 20308 – 20313. [IF 9.81] [16] Striepens N, Matusch A, Kendrick KM, Mihov Y, Elmenhorst D, Becker B, Lang M, Coenen HH, Maier W, Hurlemann R, Bauer A (2014) Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology 39:74-87. [IF 5.59] [17] Becker B, Androsch L, Jahn RT, Alich T, Striepens N, Markett S, Maier W, Hurlemann R (2014) Inferior frontal gyrus preserves working memory and emotional learning under conditions of impaired noradrenergic signaling. Frontiers in Behavioral Neuroscience 7: 197. [IF 4.76] [18] Klein JP, Becker B, Hurlemann R, Scheibe C, Colla M, Heuser I (2014) Effect of specific psychotherapy for chronic depression on neural responses to emotional faces. Journal of Affective Disorders 166: 93 – 97. [IF 3.57] [19] Wagner D, Koester P, Becker B, Gouzoulis-Mayfrank E, Hellmich M, Daumann J (2014) A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users. Psychopharmacology e-publication 08/2014. [IF 4.06] [20] Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE, Grinevich V, Kendrick KM, Maier W, Hurlemann R (2014) Oxytocin facilitates the extinction of conditioned fear in humans. Biol. Psychiatry (in press) [IF 8.93] [21] Hu J*, Qi S*, Becker B*, Luo L, Gao S, Gong Q, Hurlemann R, Kendrick KM (2015) Oxytocin selectively facilitates learning with social feedback and increases activity and functional connectivity in emotional memory and reward processing regions. Human brain mapping (in press) [IF 6.92] (*co-lead authors) [22] Haeusler AN, Becker B,Bartling M, Weber B (2015) Goal or Gold: Overlapping Reward Processes in Soccer Players upon Scoring and Winning Money. PLoS ONE (in press) [IF 3.53] [23] Becker B, Wagner D, Koester P, Tittgemeyer M, Mercer-Chalmers-Bender K, Hurlemann R, Zhang J, Gouzoulis-Mayfrank E, Kendrick KM, Daumann J (2015) Smaller amygdala and medial prefrontal cortex predict escalating stimulant use. Brain (accepted on March 06. 2015) [IF 10.23]